XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Gilead Sciences reported Q1 2026 EPS of $1.61, up 54.8% from $1.04 a year ago, on total revenues of $7.0 billion. The company immediately raised its full-year revenue guidance, signaling management's confidence th…
Gilead Sciences (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transact…
Gilead Sciences Inc (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed tran…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 4/30/2026 | Kramer Kelly A. | — | GRANT | 4,884 | — | — |
| 4/30/2026 | Kramer Kelly A. | — | GRANT | 1,146 | — | — |
| 4/30/2026 | MANWANI HARISH | — | GRANT | 4,884 | — | — |
| 4/30/2026 | MANWANI HARISH | — | TAX_WITHHOLD | -224 | $131 | $29,308 |
| 4/30/2026 | MANWANI HARISH | — | GRANT | 1,146 | — | — |
| 4/30/2026 | WELTERS ANTHONY | — | GRANT | 4,884 | — | — |
| 4/30/2026 | WELTERS ANTHONY | — | GRANT | 1,146 | — | — |
| 4/30/2026 | Rodriguez Javier | — | GRANT | 4,884 | — | — |
| 4/30/2026 | Rodriguez Javier | — | GRANT | 1,146 | — | — |
| 4/30/2026 | LOVE TED W | — | GRANT | 4,884 | — | — |
| 4/30/2026 | LOVE TED W | — | GRANT | 1,146 | — | — |
| 4/30/2026 | Horning Sandra | — | GRANT | 4,884 | — | — |
| 4/30/2026 | Horning Sandra | — | GRANT | 1,146 | — | — |
| 4/30/2026 | BARTON JACQUELINE K | — | GRANT | 4,884 | — | — |
| 4/30/2026 | BARTON JACQUELINE K | — | GRANT | 1,146 | — | — |
| 4/30/2026 | Bluestone Jeffrey | — | GRANT | 4,884 | — | — |
| 4/30/2026 | Bluestone Jeffrey | — | GRANT | 1,146 | — | — |
| 4/28/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -3,050 | $130 | $396,534 |
| 4/28/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -6,950 | $129 | $895,075 |
| 4/15/2026 | Dickinson Andrew D | Chief Financial Officer | SELL | -3,000 | $141 | $422,880 |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 121,097,336 | $14,863,487,020 | — | 1/29/2026 |
| BlackRock | 120,632,023 | $8,276,563,065 | — | 8/13/2024 |
| Fidelity (FMR) | 65,579,490 | $8,049,226,574 | — | 2/17/2026 |
| State Street | 60,240,518 | $7,393,921,179 | — | 2/13/2026 |
| JP Morgan Chase | 23,871,863 | $2,930,032,699 | — | 2/11/2026 |
| Citadel Advisors | 6,057,220 | $743,463,183 | — | 2/17/2026 |
| AQR Capital | 2,694,944 | $330,777,425 | — | 2/17/2026 |
| Millennium Management | 971,219 | $119,207,420 | — | 2/17/2026 |
| DE Shaw | 300,405 | $36,871,710 | — | 2/17/2026 |
| Bridgewater Associates | 292,406 | $35,889,912 | — | 2/13/2026 |
| Point72 | 59,600 | $7,315,304 | — | 2/17/2026 |
| Two Sigma | 11,100 | $1,362,414 | — | 2/17/2026 |